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Time will show whether the results reported by Zhu and 
colleagues2 can be achieved in other centres and whether 
this technique will become an accepted palliative 
treatment option. Regional diﬀ erences in infrastructure, 
expertise, and health-care economics will continue to be 
essential factors as clinicians tailor appropriate therapy 
for patients with advanced oesophageal cancer.
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Setting the bar for adjuvant treatment of melanoma
There is universal agreement about the need to improve 
adjuvant treatment for patients who have melanoma 
and are at high risk of disease recurrence after surgery.1,2 
Medical management of metastatic melanoma has 
improved greatly, with the approval of four new 
drugs that have shown clear survival beneﬁ ts in 
phase 3 randomised trials, beginning with the approvals 
of ipilimumab and vemurafenib in 2011. Eﬀ ective 
adjuvant treatment—whether with approved drugs 
or those in development—is important to minimise 
melanoma recurrence and death. The American Society 
of Clinical Oncology has published guidance that aims 
to improve the standard of clinical trials in metastatic 
breast, colon, lung, and pancreatic cancers by setting 
a higher bar for treatment expectations.3  Where 
should the bar then be set for clinical trials of adjuvant 
treatment in patients with melanoma? How do the 
results of the AVAST-M trial,4 which assessed the role 
of bevacizumab as adjuvant treatment for patients 
with stage III melanoma at high risk of recurrence, help 
inform our deliberations?
The availability of new drugs with clear eﬀ ects on 
metastatic melanoma provides a strong rationale for 
their investigation in adjuvant trials.  AVAST-M began 
before the approval of ipilimumab and vemurafenib, 
but even today there is little evidence from trials 
in metastatic disease to suggest that adjuvant 
bevacizumab would be beneﬁ cial in patients with 
melanoma. Findings from a randomised phase 2 
study5 of carboplatin and paclitaxel plus bevacizumab 
or placebo in patients with metastatic melanoma 
showed no improvement in progression-free survival. 
Moreover, adjuvant use of bevacizumab has not 
improved survival in patients with any other tumour 
type to date.6 Dosage is also an important consideration: 
the AVAST-M investigators studied bevacizumab given 
at a dose of 7·5 mg/kg whereas other studies have 
assessed bevacizumab given at a dose of 10–15 mg/kg, 
which could have aﬀ ected the results. Future adjuvant 
trials in patients with melanoma need a strong rationale 
and design, but whether known eﬃ  cacy of the agent in 
in metastatic melanoma is an absolute requirement for 
successful adjuvant therapy remains to be deﬁ ned.
The choice of overall survival as the primary endpoint 
of the AVAST-M study was clearly an appropriate one, 
with no signiﬁ cant diﬀ erence noted between patients 
in the bevacizumab group and those in the observation 
group (hazard ratio [HR] 0·97, 95% CI 0·78–1·22; 
p=0·76). The suitability of relapse-free survival as the 
primary endpoint in melanoma adjuvant trials bears 
further scrutiny: does having drugs that improve overall 
survival in patients with stage IV melanoma negate the 
value of relapse-free survival in the adjuvant setting, 
or might rapidly  evolving and improving treatment 
3 Guo J, Teng G, Zhu G, et al. Self-expandable esophageal stent loaded with 
¹²⁵I seeds:  initial experience in patients with advanced esophageal cancer. 
Radiology 2008; 247: 547–81.
4 Homs MYF, Styerberg EW, Eijkenboom WMH, et al. Single-dose 
brachytherapy versus metal stent placement for the palliation of dysphagia 
from oesophageal cancer: multicentre randomised trial. Lancet 2004; 
364: 1497–504.
5 Bick BL, Song LMWK, Buttar NS, et al. Stent-associated esophagorespiratory 
ﬁ stulas:  incidence and risk factors. Gastrointest Endoscopy 2013; 77: 181–89.
6 Bergquist H, Johnsson E, Nyman J, et al. Combined stent insertion and 
single high-dose brachytherapy in patients with advanced esophageal 
cancer—results of a prospective safety study. Dis Esophagus 2012; 
25: 410–15.
7 Amdal CD, Jacobsen A, Sandstad B, Warloe T, Bjordal K. Palliative 
brachytherapy with or without primary stent placement in patients with 
oesophageal cancer, a randomized phase III trial. Radiother Oncol 2013; 
107: 428–33.
8 Wenger U, Johnsson E, Bergquist H, et al. Health economic evaluation of 
stent or endoluminal brachytherapy as a palliative strategy in patients with 
incurable cancer of the oesophagus or gastro-oesophageal junction:  
results of a randomized clinical trial.  Eur J Gastroenterol Hepatol 2005; 
17: 1369–77.
Published Online
April 16, 2014
http://dx.doi.org/10.1016/
S1470-2045(14)70177-9
See Articles page 620
CN
RI
/S
cie
nc
e 
Ph
ot
o 
Li
br
ar
y
Comment
548 www.thelancet.com/oncology   Vol 15   May 2014
strategies actually accentuate the importance of 
delaying recurrence?  When relapse-free survival is 
used as a primary or key secondary endpoint, the 
investigational agent should be compared with the 
standard already set by interferon. Previous studies7,8 
of adjuvant interferon have shown improvements in 
relapse-free survival in the range of 13–38%,  and results 
for relapse-free survival from the ipilimumab adjuvant 
trials (ClinicalTrials.gov, numbers NCT00636168 and 
NCT01274338) are eagerly awaited. 
In the AVAST-M trial, disease-free interval was 
improved in patients in the bevacizumab group 
compared with those in the observation group 
(HR 0·83, 95% CI 0·70–0·98; p=0·03). Disease-free 
interval is subtly diﬀ erent from relapse-free survival 
because deaths due to non-melanoma causes are not 
included in its calculation; as such, relapse-free survival 
should remain the standard relapse endpoint for trials 
of adjuvant melanoma.  Even if we assume that relapse-
free survival was improved by the same amount as 
disease-free interval in the AVAST-M trial, and that this 
improvement was statistically signiﬁ cant, bevacizumab 
does not surpass the eﬀ ectiveness of interferon 
suﬃ  ciently enough to justify its use in clinical practice.
In the preplanned interim analysis of AVAST-M, 
patients in the bevacizumab group with BRAF mutant 
melanoma had a longer disease-free interval than did 
those in the observation group, whereas no diﬀ erence 
was noted between groups for patients with BRAF 
wild-type melanoma. Enthusiasm for this observation 
should be tempered by the ﬁ nding that the test for 
interaction between treatment and BRAF status was 
not signiﬁ cant (p=0·10).4 Furthermore, a phase 2 study 
of bevacizumab plus temozolomide chemotherapy 
in patients with metastatic melanoma showed the 
opposite result—better survival for BRAF wild-type 
melanoma.9 Either way, the rationale for improved 
outcomes for patients given bevacizumab in mutation-
deﬁ ned subsets is not well elucidated, and would need 
further study in prospective trials prior to acceptance as 
established fact.  
Although major gains have been shown in systemic 
treatments for metastatic melanoma, prevention 
of recurrence in high-risk resected patients remains 
a priority.  Interferon is the only approved adjuvant 
treatment for resected melanoma, with several studies 
showing improvement in relapse-free survival7,8 and 
meta-analyses showing small improvements in overall 
survival,2 thus setting the bar for future adjuvant 
trials. Adjuvant bevacizumab has not yet improved 
overall survival, and although disease-free interval is 
statistically improved in the AVAST-M trial, its beneﬁ ts 
seem to be, at best, similar to the relapse-free-survival 
beneﬁ t of interferon. Other variables should also be 
considered, such as patient selection and toxic eﬀ ects 
(of note, only 361 [54%] of 652 patients completed 
the planned treatment, with unacceptable toxic eﬀ ects 
nearly as common as disease recurrence as a reason 
for discontinuation), and balanced with the observed 
eﬃ  cacy. Longer follow-up of patients in the AVAST-M 
trial will help to better deﬁ ne the risk versus the beneﬁ ts 
of adjuvant bevacizumab, but in the meantime, we 
all need to think about where to set the bar for future 
progress.
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